Work

Abstract CT035: Pharmacokinetics (PK), safety, and tolerability of pembrolizumab with berahyaluronidase alfa administered subcutaneously Q3W in participants with advanced melanoma

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct035

Authors: Corlia Coetzee, Richard Khanyile, Graham Cohen, Georgina McAdam, Cathryn Walton, Sze Wai Chan, Bernardo Rapoport, Christian Caglevic, Patricio Yañez, Mallika Lala, Gina Song, Julia W. Cohen, Carlos Rojas

Institutions: Steve Biko Hospital, Life Groenkloof Hospital, The Medical Oncology Centre of Rosebank, University of Pretoria, Fundación Arturo López Pérez, Merck & Co., Inc., Rahway, NJ, USA (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409822373

Cites:

Cited by: 2

Related to: 10